Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2<sup>mut</sup> MBC).
X. Cynthia(Washington University in St. Louis), Matthew J. Ellis(Guardant (United States)), Matthew P. Goetz(Mayo Clinic), Carey K. Anders(Duke University), Hussam Al‐Kateb(Washington University in St. Louis), Mark D. Pegram(Stanford University), Christy Russell(University of Southern California), Timothy Pluard(Southwestern Medical Center), Philippe L. Bédard(Princess Margaret Cancer Centre), Melody Cobleigh(Rush University Medical Center), Andres Forero(University of Alabama at Birmingham), Polly Niravath(Houston Methodist), Caroline Bumb(Washington University in St. Louis), Daniel F. Hayes(University of Michigan–Ann Arbor), Rachel A. Freedman(Dana-Farber Cancer Institute), Michael Naughton(Boston College), Debu Tripathy(The University of Texas MD Anderson Cancer Center), Ron Bose(University Hospitals Seidman Cancer Center), Kimberly Blackwell(Duke University), Feng Gao(Washington University in St. Louis)
Cited by 17
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography
|CA A Cancer Journal for Clinicians|2007|2.6k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k